fda banning tirzepatide Is Legal in 2026? Status, Compounding Ban & FDA BANS Compounded Tirzepatide! Now

And while the drugs safety profile appears to be in line with approved GLP-1 drugs, at least some people discontinued taking retatrutide due to the drugs adverse effects

Germany's undiagnosed Type-2 diabetes population represents a systematic screening and diagnosis expansion opportunity

Currently, Tirzepatide is FDA-approved for treating type 2 diabetes

02.20.25 Large analysis of diabetic patients found increase in NAION An analysis of 37.1 million adults with type 2 diabetes across 14 databases found further evidence of an association between semaglutide and NAION. 02.04.25 MDL continued to grow leading into February The total number of cases in the GLP-1 MDL grew to 1,443